Bolt Biotherapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bolt biotherapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bolt Biotherapeutics Today - Breaking & Trending Today

Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Grows By 12.6%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 1,960,000 shares, an increase of 12.6% from the February 29th total of 1,740,000 shares. Currently, 8.2% of the shares of the stock are short sold. Based […] ....

Bolt Biotherapeutics Company Profile , Bolt Biotherapeutics Inc , Jpmorgan Chase Co , Newtyn Management , Geode Capital Management , York Mellon Corp , Get Free Report , New York Mellon Corp , Capital Management , Occudo Quantitative Strategies , Quantitative Strategies , Bolt Biotherapeutics , Nasdaq Bolt ,

Bolt Biotherapeutics (NASDAQ:BOLT) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q1 2024 earnings at ($0.47) EPS, Q2 2024 earnings at […] ....

Jpmorgan Chase Co , Tower Research Capital , Bolt Biotherapeutics Inc , Cubist Systematic Strategies , Prudential Financial Inc , Free Report , Research Capital , Systematic Strategies , Get Free Report , Bolt Biotherapeutics , Nasdaq Bolt , Reiterated Rating , Hc Wainwright ,

Vivo Capital Viii, Llc Sells 54,700 Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) major shareholder Vivo Capital Viii, Llc sold 54,700 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $0.92, for a total transaction of $50,324.00. Following the completion of the sale, the insider now owns 113,119 […] ....

Stifel Nicolaus , Renaissance Technologies , Vivo Capital Viii Llc , Millennium Management , York Mellon Corp , Bolt Biotherapeutics Inc , Cubist Systematic Strategies , Get Free Report , Vivo Capital Viii , Capital Viii , New York Mellon Corp , Bolt Biotherapeutics , Nasdaq Bolt , Insider Trading , Nsider Trades ,

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Growth in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 1,650,000 shares, an increase of 5.8% from the September 30th total of 1,560,000 shares. Based on an average daily trading volume, of 116,100 […] ....

Stifel Nicolaus , Cubist Systematic Strategies , Millennium Management , Bolt Biotherapeutics Inc , York Mellon Corp , Renaissance Technologies , Get Free Report , New York Mellon Corp , Bolt Biotherapeutics , Nasdaq Bolt ,

Bolt Biotherapeutics: First Patient Dosed In Clinical Trial Of BDC-3042

Bolt Biotherapeutics (BOLT) announced the first patient has been dosed with BDC-3042 in the single-agent dose-escalation portion of the first-in-human Phase 1/2 clinical study. ....

Shelley Ackerman , More Such Health News , Preclinical Project Team , Project Team Lead , Bolt Biotherapeutics ,